文献速递妇科

木犀草素下调牛痘相关激酶1通过激活p53信号通路抑制卵巢癌细胞增殖

Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
PubMed 文献 · Gynecol Oncol · 2023-04-17

本研究探讨木犀草素靶向牛痘相关激酶1(VRK1)对高级别浆液性卵巢癌(HGSOC)的作用。体外实验显示木犀草素抑制HGSOC细胞增殖、增加凋亡和G2/M期细胞周期阻滞,并激活p53信号通路;患者来源异种移植模型中口服或腹腔注射木犀草素均显著抑制肿瘤生长,且与顺铂联用具有协同效应。作者认为木犀草素可作为HGSOC有前景的联合治疗选择。

要点

  • 木犀草素抑制HGSOC细胞增殖、增加凋亡并诱导G2/M期细胞周期阻滞。
  • 木犀草素下调VRK1表达并激活p53信号通路,p53在ser15和ser46位点磷酸化。
  • 患者来源异种移植模型中口服或腹腔注射木犀草素均显著抑制肿瘤生长,与顺铂联用具有协同效应。

核心结论

  • 木犀草素对HGSOC细胞具有明显抗癌作用,可降低VRK1表达并激活p53信号通路,从而诱导凋亡和G2/M期细胞周期阻滞并抑制细胞增殖。
  • 木犀草素在体内和体外均与顺铂表现出协同效应,作者认为木犀草素可作为HGSOC有前景的联合治疗选择。

研究设计与样本

  • 研究采用磷酸激酶阵列、RNA测序以及细胞周期和凋亡实验探讨木犀草素对HGSOC细胞的作用机制。
  • 在患者来源异种移植模型中评估口服和腹腔注射木犀草素的抗癌效果,方法包括肿瘤大小评估及磷酸化p53、磷酸化组蛋白H3和活化 caspase 3 的免疫组化检测。

主要发现

  • 木犀草素降低HGSOC细胞增殖并增加凋亡及G2/M期细胞周期阻滞。
  • 与对照组相比,木犀草素处理细胞中多个基因表达失调,且木犀草素激活p53信号通路。
  • 人磷酸激酶阵列显示木犀草素处理细胞中p53上调,western blot证实p53在ser15和ser46位点磷酸化。
  • 患者来源异种移植模型中,口服或腹腔注射木犀草素均显著抑制肿瘤生长。
  • 木犀草素与顺铂联合治疗抑制肿瘤细胞增殖,尤其在顺铂耐药HGSOC细胞系中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Ovarian cancer constitutes one of the most common causes of cancer-related deaths, and preventing chemotherapy resistance and recurrence in patients with ovarian cancer remains a challenge. Herein, we aimed to identify the effect of luteolin, a novel therapeutic agent targeting vaccinia-related kinase 1 (VRK1), on high-grade serous ovarian cancer (HGSOC). METHODS: Phosphokinase array, RNA sequencing, and cell cycle and apoptosis assays were conducted to determine the underlying mechanism of the effect of luteolin on HGSOC cells. The anticancer effects of oral and intraperitoneal luteolin administration were assessed in patient-derived xenograft models via several methods, including the assessment of tumor size and immunohistochemistry of phospho-p53, phosphor-HistoneH3 and cleaved caspase 3. RESULTS: Luteolin reduced HGSOC cell proliferation and increased apoptosis and cell cycle arrest at G2/M. Compared with controls, several genes were dysregulated in luteolin-treated cells, and luteolin activated the p53 signaling pathway. The human phosphokinase array revealed distinct p53 upregulation in luteolin-treated cells, as confirmed by p53 phosphorylation at ser15 and ser46 using western blot analysis. In patient-derived xenograft models, oral or intraperitoneal luteolin administration substantially suppressed tumor growth. Moreover, combination treatment involving luteolin and cisplatin inhibited tumor cell proliferation, especially in cisplatin-resistant HGSOC cell lines. CONCLUSIONS: Luteolin demonstrated considerable anticancer effect on HGSOC cells, reduced VRK1 expression, and activated the p53 signaling pathway, thereby inducing apoptosis and cell cycle arrest in G2/M and inhibiting cell proliferation. Furthermore, luteolin exhibited a synergistic effect with cisplatin both in vivo and in vitro. Thus, luteolin can be considered a promising cotreatment option for HGSOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chang X, Tamauchi S, Yoshida K, et al. Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway. Gynecol Oncol. 2023. PMID: 37075494. doi:10.1016/j.ygyno.2023.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。